Inflammatory fibroblasts mediate resistance to neoadjuvant therapy in rectal cancer
Menée à l'aide d'un modèle murin de cancer rectal, d'organoïdes dérivés de tumeurs d'origine humaine et de cellules stromales, cette étude met en évidence un mécanisme par lequel les fibroblastes inflammatoires associés au cancer induisent la résistance des cellules cancéreuses à une chimioradiothérapie néoadjuvante
Standard cancer therapy targets tumor cells without considering possible damage on the tumor microenvironment that could impair therapy response. In rectal cancer patients we find that inflammatory cancer-associated fibroblasts (iCAFs) are associated with poor chemoradiotherapy response. Employing a murine rectal cancer model or patient-derived tumor organoids and primary stroma cells, we show that, upon irradiation, interleukin-1α (IL-1α) not only polarizes cancer-associated fibroblasts toward the inflammatory phenotype but also triggers oxidative DNA damage, thereby predisposing iCAFs to p53-mediated therapy-induced senescence, which in turn results in chemoradiotherapy resistance and disease progression. Consistently, IL-1 inhibition, prevention of iCAFs senescence, or senolytic therapy sensitizes mice to irradiation, while lower IL-1 receptor antagonist serum levels in rectal patients correlate with poor prognosis. Collectively, we unravel a critical role for iCAFs in rectal cancer therapy resistance and identify IL-1 signaling as an attractive target for stroma-repolarization and prevention of cancer-associated fibroblasts senescence.
Cancer Cell , article en libre accès, 2021